Senior Management

Søren Bregenholt
CEO
    • Independent in relation to the Company and its management: No
    • Independent in relation to major shareholders: Yes
    • Holdings in Alligator: 42,775 shares, 500,000 warrants in program TO 2022/2025 I, 1,200,000 warrants in program TO 2023/2026 I, 900,000 warrants in program TO 2024/2027 I, 41,649,000 warrants TO 12 and 20,744,500 warrants TO 13.
    • Other current positions: Chairman of A Bioscience Incentive AB and Atlas Therapeutics AB, and Board member of Oblique Therapeutics AB (publ).
    Johan Giléus
    CFO
      • Independent in relation to the Company and its management: No
      • Independent in relation to major shareholders: Yes
      • Holdings in Alligator: 20,000 shares, 20,000,000 warrants TO 12 and 10,000,000 warrants TO 13.
      Updated 2025-04-24